Selecta Biosciences Inc. [NASDAQ: SELB] stock went on a downward path that fall over -5.09% on Wednesday, amounting to a one-week price decrease of less than -37.90%. Over the last 12 months, SELB stock rose by 15.37%. The average equity rating for SELB stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $302.93 million, with 94.72 million shares outstanding and 73.10 million shares in the current float. Compared to the average trading volume of 1.33M shares, SELB stock reached a trading volume of 4097067 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Selecta Biosciences Inc. [SELB]:
Stifel have made an estimate for Selecta Biosciences Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 12, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on April 28, 2020, representing the official price target for Selecta Biosciences Inc. stock. Previously, the target price had yet another raise to $10, while Cantor Fitzgerald analysts kept a Overweight rating on SELB stock.
The Average True Range (ATR) for Selecta Biosciences Inc. is set at 0.39, with the Price to Sales ratio for SELB stock in the period of the last 12 months amounting to 45.21.
SELB Stock Performance Analysis:
Selecta Biosciences Inc. [SELB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -37.90. With this latest performance, SELB shares dropped by -25.59% in over the last four-week period, additionally plugging by 65.46% over the last 6 months – not to mention a rise of 15.37% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SELB stock in for the last two-week period is set at 33.92, with the RSI for the last a single of trading hit 27.90, and the three-weeks RSI is set at 39.22 for Selecta Biosciences Inc. [SELB]. The present Moving Average for the last 50 days of trading for this stock 3.13, while it was recorded at 2.81 for the last single week of trading, and 2.52 for the last 200 days.
Insight into Selecta Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Selecta Biosciences Inc. [SELB] shares currently have an operating margin of -785.61. Selecta Biosciences Inc.’s Net Margin is presently recorded at -828.97.
Return on Total Capital for SELB is now -240.39, given the latest momentum, and Return on Invested Capital for the company is -3,716.01. Return on Equity for this stock declined to -3,716.01, with Return on Assets sitting at -76.85. When it comes to the capital structure of this company, Selecta Biosciences Inc. [SELB] has a Total Debt to Total Equity ratio set at 229.57. Additionally, SELB Total Debt to Total Capital is recorded at 69.66, with Total Debt to Total Assets ending up at 19.36.
Reflecting on the efficiency of the workforce at the company, Selecta Biosciences Inc. [SELB] managed to generate an average of -$1,419,231 per employee. Receivables Turnover for the company is 2.67 with a Total Asset Turnover recorded at a value of 0.09.Selecta Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.50.
SELB Stock EPS
With the latest financial reports released by the company, Selecta Biosciences Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.3/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -23.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SELB.
Selecta Biosciences Inc. [SELB] Insider Position Details
There are presently around $150 million, or 65.80% of SELB stock, in the hands of institutional investors. The top three institutional holders of SELB stocks are: VIVO CAPITAL, LLC with ownership of 7,846,509, which is approximately -9.018% of the company’s market cap and around 8.70% of the total institutional ownership; MANGROVE PARTNERS, holding 5,548,857 shares of the stock with an approximate value of $14.7 million in SELB stocks shares; and ECOR1 CAPITAL, LLC, currently with $12.18 million in SELB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Selecta Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 46 institutional holders increased their position in Selecta Biosciences Inc. [NASDAQ:SELB] by around 11,549,563 shares. Additionally, 14 investors decreased positions by around 3,864,246 shares, while 8 investors held positions by with 41,090,861 shares. The mentioned changes placed institutional holdings at 56,504,670 shares, according to the latest SEC report filing. SELB stock had 28 new institutional investments in for a total of 7,465,019 shares, while 7 institutional investors sold positions of 742,849 shares during the same period.